Ceftin: Potent Antibiotic for Bacterial Infection Resolution
Ceftin
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $4.63 | $139.00 (0%) | 🛒 Add to cart |
| 60 | $3.65 | $278.00 $219.00 (21%) | 🛒 Add to cart |
| 90 | $3.31 | $417.00 $298.00 (29%) | 🛒 Add to cart |
| 120 | $3.14
Best per pill | $556.00 $377.00 (32%) | 🛒 Add to cart |
Ceftin (cefuroxime axetil) is a second-generation cephalosporin antibiotic indicated for the treatment of a wide range of bacterial infections. It functions by inhibiting bacterial cell wall synthesis, leading to bactericidal activity against susceptible organisms. This oral formulation offers broad-spectrum coverage, making it a versatile option in outpatient and certain inpatient settings. Healthcare providers value its reliability in treating respiratory, skin, and urinary tract infections with well-established efficacy and safety profiles.
Features
- Active ingredient: cefuroxime axetil
- Available in 250 mg and 500 mg oral tablets
- Broad-spectrum activity against Gram-positive and Gram-negative bacteria
- Beta-lactamase stability enhances resistance profile
- Bioavailability optimized through ester prodrug formulation
- FDA-approved for multiple infection sites
Benefits
- Effectively eradicates common bacterial pathogens responsible for respiratory and skin infections
- Reduces risk of complication progression through timely microbial clearance
- Convenient twice-daily dosing supports adherence to treatment regimens
- Demonstrated clinical success in both adult and pediatric populations (3 months and older)
- Lower recurrence rates compared to narrower-spectrum alternatives in appropriate cases
- Well-tolerated profile with extensive post-market safety data
Common use
Ceftin is commonly prescribed for bacterial pharyngitis/tonsillitis, acute bacterial otitis media, community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections. It is also used off-label for Lyme disease treatment in early disseminated stages. The medication demonstrates particular utility in outpatient settings where coverage for both Streptococcus pneumoniae and Haemophilus influenzae is required.
Dosage and direction
Administer with food to enhance absorption. Swallow tablets whole; do not crush or chew.
- Adults: 250-500 mg twice daily depending on infection severity and type
- Children (3 months+): 30 mg/kg/day divided twice daily (max 1,000 mg/day)
- Renal impairment: Adjust dose for CrCl <30 mL/min
Treatment duration typically ranges from 7-14 days based on infection type and clinical response. Complete the full course even if symptoms improve earlier.
Precautions
Monitor patients for diarrhea and potential Clostridium difficile-associated diarrhea. Use with caution in patients with gastrointestinal disease, particularly colitis. May cause false-positive urinary glucose tests when using copper reduction methods. Prolonged use may result in fungal or bacterial superinfection. Reduced efficacy possible in patients with impaired nutritional status. Consider alternative therapy in patients with history of gastrointestinal disease, particularly colitis.
Contraindications
Known hypersensitivity to cefuroxime or other cephalosporins. Patients with known anaphylactic reactions to penicillins may cross-react to cephalosporins. Avoid use in patients with phenylketonuria (contains phenylalanine). Not recommended in patients with known hypersensitivity to beta-lactam antibiotics. Contraindicated in patients with history of severe gastrointestinal reactions to cephalosporins.
Possible side effect
Common (≥1%): diarrhea, nausea, vomiting, abdominal pain, headache, dizziness, transient eosinophilia.
Less common: vaginal candidiasis, elevated transaminases, rash, urticaria, positive Coombs test.
Rare: pseudomembranous colitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, hemolytic anemia, interstitial nephritis, seizures (with renal impairment). Most adverse reactions are mild and self-limiting.
Drug interaction
Probenecid may increase cefuroxime concentrations. May reduce efficacy of oral contraceptives; recommend alternative contraception during treatment. Potential interaction with anticoagulants may increase bleeding risk. Concurrent use with other nephrotoxic drugs may enhance renal toxicity. False-positive reaction for ketones in urine may occur with nitroprusside testing.
Missed dose
Take the missed dose as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent antibiotic levels. If multiple doses are missed, contact healthcare provider for guidance.
Overdose
Symptoms may include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis may accelerate elimination. Management should be symptomatic and supportive. Maintain adequate hydration and electrolyte balance. Monitor renal function in significant overdoses. Contact poison control center for latest guidance.
Storage
Store at 20-25°C (68-77°F). Keep container tightly closed. Protect from moisture. Keep out of reach of children. Do not use after expiration date printed on packaging. Do not store in bathroom or damp areas. Discard any unused medication properly according to local regulations.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any medication. The prescribing physician should make final determinations regarding appropriate therapy based on individual patient factors. Full prescribing information should be reviewed before administration.
Reviews
Clinical studies demonstrate Ceftin’s efficacy with success rates of 85-95% across approved indications. Physicians report reliable performance in community-acquired infections with favorable tolerability profiles. Patients appreciate the convenient twice-daily dosing and rapid symptom improvement. Post-market surveillance confirms the established safety profile with over three decades of clinical use. Continued positive therapeutic outcomes support its position as a valuable antibiotic option in appropriate clinical scenarios.